Literature DB >> 14666411

Switching and combining dopamine agonists.

H Reichmann1, B Herting, A Mïller, U Sommer.   

Abstract

Switching from one dopamine agonist to another is common practice in the treatment of patients with Parkinson's disease. This paper describes some ideas on the most practical way to perform switching. In addition, it describes the possibilities of combining various dopamine agonists and discusses pros and cons for doing so.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14666411     DOI： 10.1007/s00702-003-0081-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  10 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 2.  Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson's disease.

Authors:  Lindy D Wood
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

3.  Dopamine Activation Preserves Visual Motion Perception Despite Noise Interference of Human V5/MT.

Authors:  Nada Yousif; Richard Z Fu; Bilal Abou-El-Ela Bourquin; Vamsee Bhrugubanda; Simon R Schultz; Barry M Seemungal
Journal:  J Neurosci       Date:  2016-09-07       Impact factor: 6.167

4.  Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture.

Authors:  G Gille; K Radad; H Reichmann; W-D Rausch
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

5.  Evaluation of autonomic functions of patients with multiple system atrophy and Parkinson's disease by head-up tilt test.

Authors:  Chikako Watano; Yuri Shiota; Keiichi Onoda; Abdullah Md Sheikh; Seiji Mishima; Eri Nitta; Shozo Yano; Shuhei Yamaguchi; Atsushi Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-11-28       Impact factor: 3.575

Review 6.  [Medication treatment for Parkinson's disease].

Authors:  H Reichmann
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

Review 7.  Switching and combining of dopamine agonists.

Authors:  Susann Junghanns; Theresa Glöckler; Heinz Reichmann
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

8.  Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.

Authors:  Jong-Min Kim; Sun Ju Chung; Jae Woo Kim; Beom Seok Jeon; Pritibha Singh; Stephan Thierfelder; Junji Ikeda; Lars Bauer
Journal:  BMC Neurol       Date:  2015-02-28       Impact factor: 2.474

9.  Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of 3-Hydroxymorphinan.

Authors:  Ziqiang Li; Xiuqi Bao; Xiaoguang Bai; Guoning Zhang; Juxian Wang; Mei Zhu; Yue Wang; Junmei Shang; Chanjuan Sheng; Dan Zhang; Yucheng Wang
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

10.  Sleep fragmentation as an important clinical characteristic of sleep disorders in Parkinson's disease: a preliminary study.

Authors:  Guo-En Cai; Shan Luo; Li-Na Chen; Jian-Ping Lu; Yu-Jie Huang; Qin-Yong Ye
Journal:  Chin Med J (Engl)       Date:  2019-08-05       Impact factor: 2.628
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.